MXPA03001529A - Metodos de administracion de fermacos a hepatocitos y tratmiento de infecciones causadas por virus de la familia flaviviridae. - Google Patents

Metodos de administracion de fermacos a hepatocitos y tratmiento de infecciones causadas por virus de la familia flaviviridae.

Info

Publication number
MXPA03001529A
MXPA03001529A MXPA03001529A MXPA03001529A MXPA03001529A MX PA03001529 A MXPA03001529 A MX PA03001529A MX PA03001529 A MXPA03001529 A MX PA03001529A MX PA03001529 A MXPA03001529 A MX PA03001529A MX PA03001529 A MXPA03001529 A MX PA03001529A
Authority
MX
Mexico
Prior art keywords
hepatocytes
treatment
methods
drug delivery
hepatocyte
Prior art date
Application number
MXPA03001529A
Other languages
English (en)
Inventor
Johnson Lau
Original Assignee
Ribapharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribapharm Inc filed Critical Ribapharm Inc
Publication of MXPA03001529A publication Critical patent/MXPA03001529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a un metodo para la administracion de un farmaco a un hepatocito, que incluye un paso en el cual se proporciona un compuesto que contiene un grupo carboxamidina a un hepatocito que tiene un transporte que transporta al compuesto a traves de la membrana citoplasmatica de dicho hepatocito, en donde el transporte del compuesto sustancialmente no es inhibido por la ribavirina. Ademas se contemplan metodos que incluyen un metodo para inhibir el crecimiento de un virus de la familia Flaviviridae en un sistema que contiene celulas, en el cual los compuestos contemplados son presentados a una celula en el sistema que contiene celulas.
MXPA03001529A 2000-08-22 2001-08-21 Metodos de administracion de fermacos a hepatocitos y tratmiento de infecciones causadas por virus de la familia flaviviridae. MXPA03001529A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22686900P 2000-08-22 2000-08-22
US24062700P 2000-10-13 2000-10-13
PCT/US2001/026057 WO2002015904A1 (en) 2000-08-22 2001-08-21 Methods of drug delivery to hepatocytes and treatment of flaviviridae infections

Publications (1)

Publication Number Publication Date
MXPA03001529A true MXPA03001529A (es) 2004-04-02

Family

ID=26920944

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001529A MXPA03001529A (es) 2000-08-22 2001-08-21 Metodos de administracion de fermacos a hepatocitos y tratmiento de infecciones causadas por virus de la familia flaviviridae.

Country Status (15)

Country Link
EP (1) EP1313469A1 (es)
JP (1) JP2004506684A (es)
KR (1) KR20030040416A (es)
CN (1) CN1447692A (es)
AU (1) AU2001292557A1 (es)
BR (1) BR0113388A (es)
CA (1) CA2415793A1 (es)
CZ (1) CZ2003308A3 (es)
HU (1) HUP0302884A2 (es)
IL (1) IL154167A0 (es)
MX (1) MXPA03001529A (es)
NO (1) NO20030794L (es)
PL (1) PL365744A1 (es)
RU (1) RU2003102607A (es)
WO (1) WO2002015904A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037908A1 (en) * 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US7608258B2 (en) 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
US20100112081A1 (en) 2008-10-07 2010-05-06 Bioparadox, Llc Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5959077A (en) * 1993-05-26 1999-09-28 Laboratori Balducci S.P.A. Hepatotropic conjugates of antiviral drugs carriers thereof and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CA2415793A1 (en) 2002-02-28
NO20030794L (no) 2003-04-22
WO2002015904B1 (en) 2002-07-04
JP2004506684A (ja) 2004-03-04
CN1447692A (zh) 2003-10-08
BR0113388A (pt) 2004-02-25
IL154167A0 (en) 2003-07-31
NO20030794D0 (no) 2003-02-20
CZ2003308A3 (cs) 2004-03-17
WO2002015904A1 (en) 2002-02-28
HUP0302884A2 (hu) 2003-12-29
AU2001292557A1 (en) 2002-03-04
EP1313469A1 (en) 2003-05-28
KR20030040416A (ko) 2003-05-22
PL365744A1 (en) 2005-01-10
RU2003102607A (ru) 2004-07-27

Similar Documents

Publication Publication Date Title
TW200630093A (en) Dose forms
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
TNSN08160A1 (en) Compounds and methods for inhibiting hepatitis c viral replication
GEP20115248B (en) Hcv ns3 protease inhibitors
DE60133555D1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
MY149169A (en) Method of treating cancer with a vegf antagonist and an anti-proliferative agent
MXPA05007322A (es) Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro.
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
MXPA03001529A (es) Metodos de administracion de fermacos a hepatocitos y tratmiento de infecciones causadas por virus de la familia flaviviridae.
RS20060197A (en) Macrocyclic peptides active against the hepatitis c virus
JP2010521481A5 (es)
JP2010521476A5 (es)
NO20065726L (no) Forbindelser og sammensetninger for avlevering av aktive forbindelser.
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
MXPA06000418A (es) Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral.
DE50313092D1 (de) Mittel zur behandlung von flaviviridae-infektionen
DE60025698D1 (de) Neue dialysemethode
WO2005067454A3 (en) Combination therapy for treating hepatitis c virus infection
WO2005004795A3 (en) Compositions and methods for targeted drug delivery
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
IL154299A0 (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
PL353232A1 (en) Method for delivery of therapeutic agents using a solution of dextrin
UA29537U (ru) Способ лечения генерализованного пародонтита
Tan et al. Analysis of ALS-2200, a Novel Potent Nucleotide Analog, Combination Drug Interactions in the Hepatitis C Virus (HCV) Subgenomic Replicon System: 1887
AR038465A1 (es) Metodos de suministro de droga a hepatocitos y tratamiento de infecciones de flaviviridos